Evidence map›Paper›PMID 28234079›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2017

Stool Xpert

M Chipinduro, K Mateveke, B Makamure, R A Ferrand, E Gomo

Open access · greenAbstract readComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 7 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 7 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Stool XpertIJTLD open · 2024
    Article
  13. Article
  14. Article
  15. Article
  16. Use of stool swabs in molecular transport media increases access to Xpert Ultra testing for TB in children.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

M ChipinduroUniversity of Zimbabwe College of Health Sciences, Medical Laboratory Sciences, Harare.
K MatevekeUniversity of Zimbabwe College of Health Sciences, Research Support Centre, Harare, Zimbabwe.
B MakamureBiomedical Research and Training Institute, Harare, Zimbabwe.
R A FerrandBiomedical Research and Training Institute, Harare, Zimbabwe, Zimbabwe; Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK.
E GomoUniversity of Zimbabwe College of Health Sciences, Medical Laboratory Sciences, Harare, Zimbabwe; Traditional Medical Laboratory, University of KwaZulu-Natal, Durban, South Africa.
University of Zimbabwe · ZWBiomedical Research and Training Institute · ZWLondon School of Hygiene & Tropical Medicine · GBUniversity of KwaZulu-Natal · ZA

Funding

Wellcome Trust
6 · The paper itself

Abstract

objectiveTo evaluate the diagnostic performance of Xpert® MTB/RIF on stool samples from children with clinical suspicion of pulmonary tuberculosis (PTB) at primary care clinics.

designA cross-sectional diagnostic evaluation enrolling 5-16 year olds from whom one induced sputum (IS) sample was tested for microbiological TB confirmation. Results of a single stool sample tested using Xpert were compared against microbiologically confirmed TB, defined as a positive result on sputum microscopy and/or culture and/or IS Xpert.

resultsOf 222 children enrolled, 218 had complete microbiological results. The median age was 10.6 years (interquartile range 8-13). TB was microbiologically confirmed in 19/218 (8.7%) children. Of these, respectively 5 (26%), 9 (47%) and 15 (79%) were smear-, culture- and IS Xpert-positive. Stool Xpert was positive in 13/19 (68%) microbiologically confirmed cases and 4/199 (2%) microbiologically negative cases. Stool Xpert detected 76.9% (10/13) of human immunodeficiency virus (HIV) infected and 50% (3/6) of non-HIV-infected children with microbiologically confirmed TB (P = 0.241).

conclusionStool Xpert is a potential alternative screening test for children with suspected TB if sputum is unavailable. Strategies to optimise the diagnostic yield of stool Xpert assay need further study.

Indexed as

AdolescentChildChild, PreschoolCross-Sectional StudiesFecesFemaleHumansMaleMicroscopyNucleic Acid Amplification TechniquesPolymerase Chain ReactionPrimary Health CareSputumTuberculosis, PulmonaryZimbabwe

Identifiers

PMID28234079
PMCPMC5234433
OpenAlexW2579615960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.